SOLIGENIX, INC. State and Local Income Tax Expense (Benefit), Continuing Operations
SOLIGENIX, INC. (SNGX) reported State and Local Income Tax Expense (Benefit), Continuing Operations of -$506.62 thousand for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-31.
Financial Statements › Expense Statement › Income Tax
us-gaap:StateAndLocalIncomeTaxExpenseBenefitContinuingOperations · last filed 2026-03-31
- SOLIGENIX, INC. state and local income tax expense (benefit), continuing operations for fiscal 2025 was -$506.62K.
- SOLIGENIX, INC. state and local income tax expense (benefit), continuing operations for fiscal 2024 was -$409.11K.
- SOLIGENIX, INC. state and local income tax expense (benefit), continuing operations for fiscal 2023 was -$1.77M.
- SOLIGENIX, INC. state and local income tax expense (benefit), continuing operations for fiscal 2022 was -$1.15M.
| Period end | State and Local Income Tax Expense (Benefit), Continuing Operations 12 month |
|---|---|
| 2025-12-31 | -$506.62K 10-K · filed 2026-03-31 |
| 2024-12-31 | -$409.11K 10-K · filed 2026-03-31 |
| 2023-12-31 | -$1.77M 10-K · filed 2025-03-21 |
| 2022-12-31 | -$1.15M 10-K · filed 2024-03-15 |
| 2021-12-31 | -$864.74K 10-K · filed 2023-03-31 |
| 2020-12-31 | -$836.89K 10-K · filed 2022-03-29 |
| 2019-12-31 | -$610.68K 10-K · filed 2021-03-30 |
| 2017-12-31 | -$416.81K 10-K · filed 2019-03-26 |
| 2016-12-31 | -$530.14K 10-K · filed 2018-03-15 |
| 2015-12-31 | -$488.93K 10-K · filed 2017-03-27 |
| 2014-12-31 | -$616.87K 10-K · filed 2016-03-24 |
| 2013-12-31 | -$750.36K 10-K · filed 2015-03-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Imunon, Inc. (IMNN) | United States | $0.008B | -0.56 |
| EXICURE, INC. (XCUR) | United States | $0.008B | -1.54 |
| Traws Pharma, Inc. (TRAW) | United States | $0.009B | -0.58 |
| Alzamend Neuro, Inc. (ALZN) | United States | $0.009B | |
| Ensysce Biosciences, Inc. (ENSC) | United States | $0.008B | -0.37 |
| InMed Pharmaceuticals Inc. (INM) | $0.008B | -0.65 | |
| Apimeds Pharmaceuticals US, Inc. (APUS) | United States | $0.008B | |
| FibroBiologics, Inc. (FBLG) | United States | $0.009B | -0.27 |
| CNS Pharmaceuticals, Inc. (CNSP) | United States | $0.007B | |
| Acurx Pharmaceuticals, Inc. (ACXP) | United States | $0.007B | -0.97 |